logo
MCED Screening: What Patients Need to Know

MCED Screening: What Patients Need to Know

Medscape11-07-2025
With half a million people having already received multi-cancer early detection (MCED) screening, patients are and will continue to be asking about these blood tests during their visits, physicians say.
During an Education Session at the American Society of Clinical Oncology (ASCO) 2025, several experts on these tests advised on how to approach these conversations with patients and described what they think is worth sharing about them.
Front and center for the panelists of the session entitled, 'Multicancer Early Detection Testing: Are There Cures Without Costs?' Was that there are not yet any randomized clinical trial results showing that a positive MCED test result will actually decrease cancer mortality or even morbidity.
'We need to see trials that show something has changed for the better for the patient. Does it really move the needle for that patient, or are we just finding [the cancer] earlier?' said Jennifer Litton, MD, professor, vice president of clinical research, and interim chair of breast medical oncology at The University of Texas MD Anderson Cancer Center in Houston.
'Are we improving survival, improving treatment, or improving toxicity?' she asked, during her presentation in the session. Beyond the physical toxicity of treatments, there is also financial toxicity to consider.
Although there are several MCED tests in the pipeline, GRAIL's Galleri test is the only one currently on the market.
Studies of Galleri and other MCED tests still in development have so far shown that these blood-based screenings can, indeed, detect circulating tumor DNA (ctDNA) in patients who are asymptomatic, often suggesting cancer long before regular screening tests confirm it. But, thus far, there is no evidence that earlier detection saves lives, or can allow for less aggressive treatment.
While Carmen Estela Guerra, MD, the chair of the session, acknowledged that clinicians are not obligated to initiate discussions about MCEDs until more is known about their effectiveness, as guidance from the American Cancer Society states, she provided starting points and resources for discussing these tests with patients.
'It's really important…to understand that patients may hear about Galleri tests, as will primary care physicians that might consult with us. And so we have to consider…that once people approach us, patients, primary care clinicians, that we really take this opportunity…to make sure that patients are up to date with evidence-based cancer screenings, whatever cancer screenings are appropriate for their age, sex, family history, tobacco history, and other risk factors,' said Guerra at the meeting.
She added that if patients inquire about MCEDs, clinicians first want to determine if they are even eligible for testing.
Guerra, who is professor of medicine at the University of Pennsylvania, and a general internist and cancer equity researcher at the Abramson Cancer Center, both in Philadelphia, also provided answers to several other questions patients may ask about the Galleri and other MCED tests during her presentation.
Who is Eligible to Receive the Galleri Test?
According to the Galleri website, anyone older than 50 years is eligible to receive these tests.
'Some experts have said that perhaps other people who might be eligible are those with family histories or personal histories of cancer in the past. And then, perhaps, even people with known genetic mutations, who are at risk for multiple cancers, may be eligible individuals,' Guerra said. 'Again, this is expert opinion. And you may read about these potential eligibility [criteria]. But the truth is, we just don't know yet.'
Who Can't Receive This Screening?
'Some people have proposed pediatric populations, pregnant individuals, and patients who have had a cancer diagnosis within the past 3 years are not eligible for MCED testing,' Guerra said. 'In fact, they were excluded from the [ongoing] NHS-Galleri study.'
An MCED consortium was created, which was a private, public partnership between the MCED companies, the American Cancer Society, and many other experts. This provided a list of additional risk factors 'that, perhaps in the future, may also help us identify who is a potential candidate for MCED testing,' she continued.
That list, which was published in an article in JCO Precision Oncology in November 2021, includes:
Using alcohol
Having been exposed to cancer-causing substances (eg, fire smoke, tobacco smoke, radiation, and sunlight)
Being immunosuppressed
Having been exposed to infectious agents (eg, viruses and parasites)
Having Overweight/Obesity
Using Tobacco
How to Approach Discussions With Patients and Clinicians
One of the approaches that's being adapted to clinicians discussing MCEDs with patients and other clinicians is the shared decision framework, Guerra explained.
That shared decision framework emphasizes that MCEDs are not replacements for evidence-based cancer screening, but that they could be additive in some cases, she said.
The shared decision model is a talk model approach.
'It starts with the option or choice talk. And that's about basic education about MCEDs, what they detect, who is eligible, which tests are available, and how much does it cost,' she said.
The option talk involves addressing what the potential benefits and harms are, the likelihood of harm, interpretation of the tests, test uncertainties, and the option of not testing at all, Guerra continued.
Finally, to follow this model, clinicians help patients decide whether to have the testing.
Part of this includes recognizing that 'some patients, after hearing all this, may not want to have the test. And that's OK, too,' she said.
Guerrera also pointed out that other option- and decision-related talk points for approaching these conversations were published in April in the American Society of Clinical Oncology Education Book . She and her colleagues coauthored this article.
One example of a 'decision talk' point in the article aimed at answering how to decide whether to have these tests is that 'MCED tests are not a recommended part of your routine cancer screening at this time.'
Another is: 'If you are unsure about getting tested, it may be best to wait. We can always revisit your decisions as more information becomes available.'
What are the Advantages and Disadvantages of the Tests?
During her presentation, Guerra also described some of the advantages and disadvantages to MCED screening that clinicians could speak about with their patients.
'The advantages are, obviously, that screening can occur for multiple cancers at the same time, and that MCEDs can detect cancers [for which we currently don't have a modality], and that MCEDs have increased positive predictive value compared to single cancer screening tests,' she said.
'But you can see there's a lot of potential disadvantages, at the moment. Much of this is because we don't have information to inform our patients, including that patients should know that MCEDs are not currently covered by insurance,' Guerra continued. 'In addition, there's no consensus or guidelines for who should be tested and what the best testing pathway is for a positive MCED. That even if they have a 'no cancer signal' detected, it does not rule out future cancer diagnoses.'
With these tests, 'consequential cancers could be found early, but the patient may not live longer because of overdiagnosis,' she said.
More potential disadvantages to these tests, which Guerra included in a slide for her presentation, included:
Possible harm from unnecessary diagnostic procedures due to false positives or missed diagnoses due to false negatives
Overdiagnosis and overtreatment of cancers that would have otherwise never bothered a patient
Increased inequities if tests are not widely available, affordable, and acceptable to minority groups
What's Missing and What to Offer Patients Who Want an MCED Test?
'One of the things that's really missing to guide clinicians right now is what to do with those positive cancer signals. And there is no document that has some guidance for any of us, or even our oncologists because many clinicians, primary care clinicians, will refer those patients to oncologists,' Guerra said.
'Given the uncertainties about MCEDs, one of the options that we might offer our patients that want to have an MCED is a recommendation to enroll [in one of the MCED studies], where they will be tracked as part of the clinical trial, and where outcomes will be evaluated and inform future practice.'
Among these trials is the Vanguard study, a National Cancer Institute study that is being designed across nine geographical areas, that will enroll 24,000 participants in the US. The first two tests that will be used in this trial are Shield and Avantect, and others may be used as well, according to Guerra.
The objective of the Vanguard study is to determine if patients will be willing to even be randomized to this study and determine adherence and feasibility questions about the study, that will later inform a larger study, she said.
Another trial patients can enroll in is the REACH initiative, which is a collaboration between Grail and Medicare that will prospectively look at 50,000 Medicare beneficiaries to compare patients receiving usual care with those receiving the Galleri test.
The investigators for this study 'will try to answer questions about whether there are reduced diagnoses of late stage, stage IV, and the safety and healthcare utilization,' Guerra said. This is a 3-year study across 50 sites that was initiated about 2 years ago.
More Information About Galleri
The Galleri test has a list price of $949 and is available only by prescription. It's designed to flag the possibility of up to 50 different cancers by detecting ctDNA in a blood sample.
Because Galleri is not approved by the FDA, most insurance would not cover it or any follow-ups prompted by a positive result, according to the American Cancer Society.
GRAIL has applied for Breakthrough Device Designation and Pre-Market Approval for Galleri. The company is currently authorized to perform the test at its laboratory, which is certified by the Centers for Medicare & Medicaid Services under the Clinical Laboratory Improvement Amendments of 1988.
Litton disclosed financial relationships with UpToDate, Physicans' Education Resource, Merck, Pfizer, and Certis.
Guerra reported financial relationships with BEAM Therapeutics, Crispr Therapeutics, Editas Medicine, Intellia Therapeutics, National Comprehensive Cancer Network, GlaxoSmithKline, Guardant Health, Impulse, Natera, Roche, Janssen, and Genentech.
Kate Johnson contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates
U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

Yahoo

timea few seconds ago

  • Yahoo

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

HOUSTON, July 23, 2025--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three months and six months ended June 30, 2025, on Wednesday, August 6, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 7, 2025. Conference Call Date: Thursday, August 7, 2025 Time: 10:30 am Eastern / 9:30 am Central Dial-In Number: (800) 343-4136 Primary or (203) 518-9843 Alternate Conference ID: USPHQ225 (In order to join this conference call,you will be required to provide the Conference ID listed above) To participate, please call in 15 minutes prior to start time. To listen to the live call, please go to and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025 at USPH's website. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 768 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release. View source version on Contacts U.S. Physical Therapy, Hendrickson, Chief Financial OfficerEmail: Chendrickson@ Chris Reading, Chief Executive Officer(713) 297-7000 Three Part AdvisorsJoe Noyons(817) 778-8424

The president vows to slash medication cost to an unachievable degree.
The president vows to slash medication cost to an unachievable degree.

Yahoo

timea few seconds ago

  • Yahoo

The president vows to slash medication cost to an unachievable degree.

President Donald Trump has promised to reduce American drug prices by mathematically impossible figures of up to '1400 percent.' Speaking during a White House event attended by Republican members of Congress and his Cabinet, Trump said he would tackle the long-running issue of high medication costs in the U.S. But Trump did not set any achievable targets for that aim, instead outlining a range of percentages which would yield negative prices, meaning drug companies would have to pay people to take their medications.

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

Yahoo

timea few seconds ago

  • Yahoo

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store